Skip to main content

Articles

Page 1 of 41

  1. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Elena M. Yubero-Serrano, Juan F. Alcalá-Diaz, Francisco M. Gutierrez-Mariscal, Antonio P. Arenas-de Larriva, Patricia J. Peña-Orihuela, Ruth Blanco-Rojo, Javier Martinez-Botas, Jose D. Torres-Peña, Pablo Perez-Martinez, Jose M. Ordovas, Javier Delgado-Lista, Diego Gómez-Coronado and Jose Lopez-Miranda

    Citation: Cardiovascular Diabetology 2021 20:79

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2021 20:72

  2. Patients with type 2 diabetes (T2DM) have a prothrombotic state that needs to be fully clarified; microparticles (MPs) have emerged as mediators and markers of this condition. Thus, we investigate, in vivo, in...

    Authors: Alessandra Giannella, Giulio Ceolotto, Claudia Maria Radu, Arianna Cattelan, Elisabetta Iori, Andrea Benetti, Fabrizio Fabris, Paolo Simioni, Angelo Avogaro and Saula Vigili de Kreutzenberg

    Citation: Cardiovascular Diabetology 2021 20:77

    Content type: Original investigation

    Published on:

  3. Insulin resistance has been demonstrated to be involved in the pathogenesis of atherosclerotic cardiovascular diseases (ASCVDs). This study evaluated the association between the triglyceride–glucose (TyG) inde...

    Authors: Xiaobo Ding, Xiaozhen Wang, Jing Wu, Manli Zhang and Meizi Cui

    Citation: Cardiovascular Diabetology 2021 20:76

    Content type: Original investigation

    Published on:

  4. The 6th Cardiovascular Outcome Trial (CVOT) Summit “Cardiovascular and Renal Outcomes 2020” was the first to be held virtually on October 29–30, 2020. As in previous years, this summit served as reference meet...

    Authors: Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J. L. Heersprink, Mikhail Kosiborod, Christoph Wanner and Eberhard Standl

    Citation: Cardiovascular Diabetology 2021 20:75

    Content type: Commentary

    Published on:

  5. The glucose-lowering independent effect of sodium glucose cotransporter-2 inhibitors (SGLT2i) on arterial wall function has not yet been clarified. This study aims to assess whether SGLT2i treatment can attenu...

    Authors: Andrei C. Sposito, Ikaro Breder, Alexandre A. S. Soares, Sheila T. Kimura-Medorima, Daniel B. Munhoz, Riobaldo M. R. Cintra, Isabella Bonilha, Daniela C. Oliveira, Jessica Cunha Breder, Pamela Cavalcante, Camila Moreira, Filipe A. Moura, Jose Carlos de Lima-Junior, Helison R. P. do Carmo, Joaquim Barreto, Wilson Nadruz…

    Citation: Cardiovascular Diabetology 2021 20:74

    Content type: Original investigation

    Published on:

  6. Essential hypertension and type 2 diabetes mellitus (T2DM) are two common chronic diseases that often coexist, and both of these diseases can cause heart damage. However, the additive effects of essential hype...

    Authors: Wei-feng Yan, Yue Gao, Yi Zhang, Ying-kun Guo, Jin Wang, Li Jiang, Yuan Li and Zhi-gang Yang

    Citation: Cardiovascular Diabetology 2021 20:73

    Content type: Original investigation

    Published on:

  7. Peripheral artery disease (PAD) is recognized as a significant predictor of mortality and adverse cardiovascular outcomes in patients with coronary heart disease (CHD). In fact, coexisting PAD and CHD is stron...

    Authors: Elena M. Yubero-Serrano, Juan F. Alcalá-Diaz, Francisco M. Gutierrez-Mariscal, Antonio P. Arenas-de Larriva, Patricia J. Peña-Orihuela, Ruth Blanco-Rojo, Javier Martinez-Botas, Jose D. Torres-Peña, Pablo Perez-Martinez, Jose M. Ordovas, Javier Delgado-Lista, Diego Gómez-Coronado and Jose Lopez-Miranda

    Citation: Cardiovascular Diabetology 2021 20:72

    Content type: Original investigation

    Published on:

    The Correction to this article has been published in Cardiovascular Diabetology 2021 20:79

  8. Diabetes mellitus is a common comorbidity of atrial fibrillation (AF), which can complicate the management of AF. The pharmacology of oral anticoagulants (OACs) have been implicated in pathogenesis of diabetes...

    Authors: Ching-Lung Cheung, Chor-Wing Sing, Wallis C. Y. Lau, Gloria H. Y. Li, Gregory Y. H. Lip, Kathryn C. B. Tan, Bernard M. Y. Cheung, Esther W. Y. Chan and Ian C. K. Wong

    Citation: Cardiovascular Diabetology 2021 20:71

    Content type: Original investigation

    Published on:

  9. The prevalence of hypertension and obesity has increased significantly in recent decades. Hypertension and obesity often coexist, and both are associated with increased cardiovascular mortality. Obese hyperten...

    Authors: Yahya M. Naguib, Rehab M. Samaka, Mohamed S. Rizk, Omnia Ameen and Shaimaa M. Motawea

    Citation: Cardiovascular Diabetology 2021 20:70

    Content type: Original investigation

    Published on:

  10. During COVID-19 pandemic, elective invasive cardiac procedures (ICP) have been frequently cancelled or postponed. Consequences may be more evident in patients with diabetes.

    Authors: Raúl Moreno, José-Luis Díez, José-Antonio Diarte, Pablo Salinas, José María de la Torre Hernández, Juan F. Andres-Cordón, Ramiro Trillo, Juan Alonso Briales, Ignacio Amat-Santos, Rafael Romaguera, José-Francisco Díaz, Beatriz Vaquerizo, Soledad Ojeda, Ignacio Cruz-González, Daniel Morena-Salas, Armando Pérez de Prado…

    Citation: Cardiovascular Diabetology 2021 20:69

    Content type: Original investigation

    Published on:

  11. Adiposity is a major component of the metabolic syndrome (MetS), low muscle strength has also been identified as a risk factor for MetS and for cardiovascular disease. We describe the prevalence of MetS and ev...

    Authors: Jose P. Lopez-Lopez, Daniel D. Cohen, Daniela Ney-Salazar, Daniel Martinez, Johanna Otero, Diego Gomez-Arbelaez, Paul A. Camacho, Gregorio Sanchez-Vallejo, Edgar Arcos, Claudia Narvaez, Henry Garcia, Maritza Perez, Dora I. Molina, Carlos Cure, Aristides Sotomayor, Álvaro Rico…

    Citation: Cardiovascular Diabetology 2021 20:68

    Content type: Original investigation

    Published on:

  12. Major prospective randomized clinical safety trials have demonstrated beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose co-transporter-2 inhibitors (...

    Authors: Moa Lugner, Naveed Sattar, Mervete Miftaraj, Jan Ekelund, Stefan Franzén, Ann-Marie Svensson and Björn Eliasson

    Citation: Cardiovascular Diabetology 2021 20:67

    Content type: Original investigation

    Published on:

  13. Given the rising prevalence of dysglycemia and disparities in heart failure (HF) burden, we determined race- and sex-specific lifetime risk of HF across the spectrum of fasting plasma glucose (FPG).

    Authors: Arjun Sinha, Hongyan Ning, Faraz S. Ahmad, Michael P. Bancks, Mercedes R. Carnethon, Matthew J. O’Brien, Norrina B. Allen, John T. Wilkins, Donald M. Lloyd-Jones and Sadiya S. Khan

    Citation: Cardiovascular Diabetology 2021 20:66

    Content type: Original investigation

    Published on:

  14. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced cardiovascular risk in type 2 diabetes patients independently of glycemic control. Although angiotensin II (Ang II) and blood-derived microparticles ar...

    Authors: Sin-Hee Park, Eugenia Belcastro, Hira Hasan, Kensuke Matsushita, Benjamin Marchandot, Malak Abbas, Florence Toti, Cyril Auger, Laurence Jesel, Patrick Ohlmann, Olivier Morel and Valérie B. Schini-Kerth

    Citation: Cardiovascular Diabetology 2021 20:65

    Content type: Original investigation

    Published on:

  15. We investigated whether glycemic control affects the relation between endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus (T2DM).

    Authors: Shuai Chen, Ying Shen, Yong-Hua Liu, Yang Dai, Zhi-Ming Wu, Xiao-Qun Wang, Chen-Die Yang, Le-Ying Li, Jing-Meng Liu, Li-Ping Zhang, Wei-Feng Shen, Ri Ji, Lin Lu and Feng-Hua Ding

    Citation: Cardiovascular Diabetology 2021 20:64

    Content type: Original investigation

    Published on:

  16. Screening for coronary artery disease (CAD) remains broadly performed in patients with type 2 diabetes (T2DM), although the lack of evidence. We conduct a real-world evidence (RWE) study to assess the risk of ...

    Authors: Kamel Mohammedi, Nathalie Préaubert, Tanguy Cariou, Vincent Rigalleau, Ninon Foussard, Laurent Piazza, Céline Bairras-Martin, Thierry Couffinhal, Julien Bezin and Antoine Benard

    Citation: Cardiovascular Diabetology 2021 20:63

    Content type: Study protocol

    Published on:

  17. Type 1 diabetes mellitus (T1DM) is associated with an increased risk for cardiovascular disease (CVD) related morbidity and premature mortality. Regular physical activity plays an important role in the primary...

    Authors: Nana Wu, Shannon S. D. Bredin, Veronica K. Jamnik, Michael S. Koehle, Yanfei Guan, Erin M. Shellington, Yongfeng Li, Jun Li and Darren E. R. Warburton

    Citation: Cardiovascular Diabetology 2021 20:62

    Content type: Original investigation

    Published on:

  18. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Pratibha Singh, Isabel Goncalves, Christofer Tengryd, Mihaela Nitulescu, Ana F. Persson, Fong To, Eva Bengtsson, Petr Volkov, Marju Orho-Melander, Jan Nilsson and Andreas Edsfeldt

    Citation: Cardiovascular Diabetology 2021 20:61

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2020 19:214

  19. Women with type 2 diabetes (T2DM) have a higher excess risk for cardiovascular disease (CVD) than their male counterparts. However, whether the risk for CVD is higher in prediabetic women than men is still deb...

    Authors: Elena Succurro, Sofia Miceli, Teresa Vanessa Fiorentino, Angela Sciacqua, Maria Perticone, Francesco Andreozzi and Giorgio Sesti

    Citation: Cardiovascular Diabetology 2021 20:60

    Content type: Original investigation

    Published on:

  20. The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by car...

    Authors: Basilio Pintaudi, Alessia Scatena, Gabriella Piscitelli, Vera Frison, Salvatore Corrao, Valeria Manicardi, Giusi Graziano, Maria Chiara Rossi, Marco Gallo, Domenico Mannino, Paolo Di Bartolo and Antonio Nicolucci

    Citation: Cardiovascular Diabetology 2021 20:59

    Content type: Original investigation

    Published on:

  21. Adults who have experienced multiple cardiovascular disease (CVD) events have a very high risk for additional events. Diabetes and chronic kidney disease (CKD) are each associated with an increased risk for re...

    Authors: Demetria Hubbard, Lisandro D. Colantonio, Robert S. Rosenson, Todd M. Brown, Elizabeth A. Jackson, Lei Huang, Kate K. Orroth, Stephanie Reading, Mark Woodward, Vera Bittner, Orlando M. Gutierrez, Monika M. Safford, Michael E. Farkouh and Paul Muntner

    Citation: Cardiovascular Diabetology 2021 20:58

    Content type: Original investigation

    Published on:

  22. Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that has demonstrated cardiovascular and renal protection in patients with type 2 diabetes (T2D). We hypothesized that empaglifozin (EMPA) co...

    Authors: B. Gaborit, P. Ancel, A. E. Abdullah, F. Maurice, I. Abdesselam, A. Calen, A. Soghomonian, M. Houssays, I. Varlet, M. Eisinger, A. Lasbleiz, F. Peiretti, C. E. Bornet, Y. Lefur, L. Pini, S. Rapacchi…

    Citation: Cardiovascular Diabetology 2021 20:57

    Content type: Original investigation

    Published on:

  23. Impaired fasting glucose (IFG) is a prevalent and potentially reversible intermediate stage leading to type 2 diabetes that increases risk for cardiometabolic complications. The identification of clinical and ...

    Authors: Magdalena del Rocío Sevilla-González, Jordi Merino, Hortensia Moreno-Macias, Rosalba Rojas-Martínez, Donají Verónica Gómez-Velasco and Alisa K. Manning

    Citation: Cardiovascular Diabetology 2021 20:56

    Content type: Original investigation

    Published on:

  24. The epidemic of diabetes mellitus (DM) necessitates the development of novel therapeutic and preventative strategies to attenuate complications of this debilitating disease. Diabetic cardiomyopathy (DCM) is a ...

    Authors: Daniel Jakubik, Alex Fitas, Ceren Eyileten, Joanna Jarosz-Popek, Anna Nowak, Pamela Czajka, Zofia Wicik, Harald Sourij, Jolanta M. Siller-Matula, Salvatore De Rosa and Marek Postula

    Citation: Cardiovascular Diabetology 2021 20:55

    Content type: Review

    Published on:

  25. The prognostic importance of non-traditional risk factors for peripheral artery disease (PAD) development/progression is scarcely studied in diabetes. We investigated if carotid intima-media thickness (CIMT) a...

    Authors: Claudia R. L. Cardoso, Juliana V. Melo, Thainá R. M. Santos, Nathalie C. Leite and Gil F. Salles

    Citation: Cardiovascular Diabetology 2021 20:54

    Content type: Original investigation

    Published on:

  26. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Judith van Haare, M. Eline Kooi, Jurgen W. G. E. van Teeffelen, Hans Vink, Jos Slenter, Hanneke Cobelens, Gustav J. Strijkers, Dennis Koehn, Mark J. Post and Marc van Bilsen

    Citation: Cardiovascular Diabetology 2021 20:53

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2017 16:47

  27. Diabetes increases a patient’s risk of developing atrial fibrillation by 49%. Patients with nonvalvular atrial fibrillation are at a fivefold increased risk of stroke and die more frequently from vascular caus...

    Authors: Craig I. Coleman, Olivia S. Costa, Christopher W. Brescia, Burcu Vardar, Khaled Abdelgawwad and Nitesh Sood

    Citation: Cardiovascular Diabetology 2021 20:52

    Content type: Original investigation

    Published on:

  28. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Judith van Haare, M. Eline Kooi, Hans Vink, Mark J. Post, Jurgen W. G. E. van Teeffelen, Jos Slenter, Chantal Munts, Hanneke Cobelens, Gustav J. Strijkers, Dennis Koehn and Marc van Bilsen

    Citation: Cardiovascular Diabetology 2021 20:51

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2015 14:150

  29. Acetylcholine (ACh) plays a crucial role in the function of the heart. Recent evidence suggests that cardiomyocytes possess a non-neuronal cholinergic system (NNCS) that comprises of choline acetyltransferase ...

    Authors: Eng Leng Saw, James T. Pearson, Daryl O. Schwenke, Pujika Emani Munasinghe, Hirotsugu Tsuchimochi, Shruti Rawal, Sean Coffey, Philip Davis, Richard Bunton, Isabelle Van Hout, Yuko Kai, Michael J. A. Williams, Yoshihiko Kakinuma, Martin Fronius and Rajesh Katare

    Citation: Cardiovascular Diabetology 2021 20:50

    Content type: Original investigation

    Published on:

  30. Soluble suppression of tumorigenesis-2 (sST2) is implicated in myocardial overload and has long been recognized as an inflammatory marker related to heart failure and acute coronary syndrome, but data on the p...

    Authors: Man Li, Lei Duan, Yulun Cai, Benchuan Hao, Jianqiao Chen, Huiying Li and Hongbin Liu

    Citation: Cardiovascular Diabetology 2021 20:49

    Content type: Original investigation

    Published on:

  31. Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome, with several underlying etiologic and pathophysiologic factors. The presence of diabetes might identify an important phenotyp...

    Authors: Sibille Lejeune, Clotilde Roy, Alisson Slimani, Agnès Pasquet, David Vancraeynest, Jean-Louis Vanoverschelde, Bernhard L. Gerber, Christophe Beauloye and Anne-Catherine Pouleur

    Citation: Cardiovascular Diabetology 2021 20:48

    Content type: Original investigation

    Published on:

  32. Patients with type 2 diabetes mellitus (T2DM) are at high risk of cardiovascular mortality, but the mechanisms behind this remain unclear. Prothrombotic fibrin clot properties have been shown in T2DM and cardi...

    Authors: Agata Hanna Bryk, Małgorzata Konieczyńska, Maciej Polak, Dariusz Plicner, Maciej Bochenek and Anetta Undas

    Citation: Cardiovascular Diabetology 2021 20:47

    Content type: Original investigation

    Published on:

  33. Triglyceride-glucose (TyG) index was recently suggested to be a reliable surrogate marker of insulin resistance. We aim to investigate the associations between baseline and long-term TyG index with subsequent ...

    Authors: Anxin Wang, Guangyao Wang, Qian Liu, Yingting Zuo, Shuohua Chen, Boni Tao, Xue Tian, Penglian Wang, Xia Meng, Shouling Wu, Yongjun Wang and Yilong Wang

    Citation: Cardiovascular Diabetology 2021 20:46

    Content type: Original investigation

    Published on:

  34. Endothelial progenitor cells (EPCs) has been shown to be dysfunctional in both type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) leading to poor regeneration of endothelium and renal perfusion. ...

    Authors: Seshagiri Rao Nandula, Nabanita Kundu, Hassan B. Awal, Beda Brichacek, Mona Fakhri, Nikhila Aimalla, Adrian Elzarki, Richard L. Amdur and Sabyasachi Sen

    Citation: Cardiovascular Diabetology 2021 20:44

    Content type: Original investigation

    Published on:

  35. Triglyceride glucose (TyG) index is considered a reliable alternative marker of insulin resistance and an independent predictor of cardiovascular (CV) outcomes. However, the prognostic value of TyG index in pa...

    Authors: Yue Zhang, Xiaosong Ding, Bing Hua, Qingbo Liu, Hui Gao, Hui Chen, Xue-Qiao Zhao, Weiping Li and Hongwei Li

    Citation: Cardiovascular Diabetology 2021 20:43

    Content type: Original investigation

    Published on:

  36. Clinical trials are often performed to investigate the effects of various types of cardiometabolic therapies on cardiovascular surrogate markers, including vascular function and biomarkers. This study platform...

    Authors: Atsushi Tanaka and Koichi Node

    Citation: Cardiovascular Diabetology 2021 20:41

    Content type: Commentary

    Published on:

  37. There are limited data on the association of diabetes mellitus (DM) and levels of glycated hemoglobin (HbA1c) with outcomes in patients with atrial fibrillation (AF).

    Authors: Andreas S. Papazoglou, Anastasios Kartas, Athanasios Samaras, Ioannis Vouloagkas, Eleni Vrana, Dimitrios V. Moysidis, Evangelos Akrivos, Georgios Kotzampasis, Amalia Baroutidou, Anastasios Papanastasiou, Evangelos Liampas, Michail Botis, Efstratios Karagiannidis, Nikolaos Stalikas, Haralambos Karvounis, Apostolos Tzikas…

    Citation: Cardiovascular Diabetology 2021 20:40

    Content type: Original investigation

    Published on:

  38. Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food an...

    Authors: Benedetta Maria Bonora, Emanuel Raschi, Angelo Avogaro and Gian Paolo Fadini

    Citation: Cardiovascular Diabetology 2021 20:39

    Content type: Original investigation

    Published on:

  39. Gender disparities in the management of dysglycaemia, defined as either impaired glucose tolerance (IGT) or type 2 diabetes (T2DM), in coronary artery disease (CAD) patients are a medical challenge. Recent dat...

    Authors: Giulia Ferrannini, Dirk De Bacquer, Pieter Vynckier, Guy De Backer, Viveca Gyberg, Kornelia Kotseva, Linda Mellbin, Anna Norhammar, Jaakko Tuomilehto, David Wood and Lars Rydén

    Citation: Cardiovascular Diabetology 2021 20:38

    Content type: Original investigation

    Published on:

  40. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Shaminie J. Athinarayanan, Sarah J. Hallberg, Amy L. McKenzie, Katharina Lechner, Sarah King, James P. McCarter, Jeff S. Volek, Stephen D. Phinney and Ronald M. Krauss

    Citation: Cardiovascular Diabetology 2021 20:37

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2020 19:208

  41. In this commentary, we introduce the concepts of removed and residual risks in conditioning thecardiorenal outlook of patients with type 2 diabetes (T2D). The removed cardiorenal risk represents the risk of pr...

    Authors: Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella and Katherine Esposito

    Citation: Cardiovascular Diabetology 2021 20:36

    Content type: Commentary

    Published on:

  42. Epicardial adipose tissue (EAT) has anatomic and functional proximity to the heart and is considered a novel diagnostic marker and therapeutic target in cardiometabolic diseases. The aim of this study was to e...

    Authors: Emmanuel Cosson, Minh Tuan Nguyen, Imen Rezgani, Sopio Tatulashvili, Meriem Sal, Narimane Berkane, Lucie Allard, Pierre-Yves Brillet and Hélène Bihan

    Citation: Cardiovascular Diabetology 2021 20:35

    Content type: Original investigation

    Published on:

  43. Recently, the European Society of Cardiology (ESC) and European Association for the Society of Diabetes (EASD) introduced a new cardiovascular disease (CVD) risk stratification model to aid further treatment d...

    Authors: Suriya Prausmüller, Michael Resl, Henrike Arfsten, Georg Spinka, Raphael Wurm, Stephanie Neuhold, Philipp E. Bartko, Georg Goliasch, Guido Strunk, Noemi Pavo, Martin Clodi and Martin Hülsmann

    Citation: Cardiovascular Diabetology 2021 20:34

    Content type: Original investigation

    Published on:

  44. Hyperglycemia has been associated with increased inflammatory indexes and larger infarct sizes in patients with obstructive acute myocardial infarction (obs-AMI). In contrast, no studies have explored these co...

    Authors: Pasquale Paolisso, Alberto Foà, Luca Bergamaschi, Francesco Donati, Michele Fabrizio, Chiara Chiti, Francesco Angeli, Sebastiano Toniolo, Andrea Stefanizzi, Matteo Armillotta, Paola Rucci, Gianmarco Iannopollo, Gianni Casella, Cinzia Marrozzini, Nazzareno Galiè and Carmine Pizzi

    Citation: Cardiovascular Diabetology 2021 20:33

    Content type: Original investigation

    Published on:

  45. While the cardioprotective benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors have been established in patients with cardiovascular disease (CVD), their advantages over other anti-diabetic drugs at ...

    Authors: Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose and Naoki Kumashiro

    Citation: Cardiovascular Diabetology 2021 20:32

    Content type: Original investigation

    Published on:

  46. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Lei Guo, Junjie Wang, Huaiyu Ding, Shaoke Meng, Xiaoyan Zhang, Haichen Lv, Lei Zhong, Jian Wu, Jiaying Xu, Xuchen Zhou and Rongchong Huang

    Citation: Cardiovascular Diabetology 2021 20:31

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2020 19:100

  47. Metformin is a first-line drug in type 2 diabetes mellitus (T2DM) treatment, yet whether metformin may increase all-cause or cardiovascular mortality of T2DM patients remains inconclusive.

    Authors: Tian Li, Rui Providencia, Nan Mu, Yue Yin, Mai Chen, Yishi Wang, Manling Liu, Lu Yu, Chunhu Gu and Heng Ma

    Citation: Cardiovascular Diabetology 2021 20:30

    Content type: Original investigation

    Published on:

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics

\